Literature DB >> 22315408

MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function.

Brooke H Miller1, Zane Zeier, Li Xi, Thomas A Lanz, Shibing Deng, Julia Strathmann, David Willoughby, Paul J Kenny, John D Elsworth, Matthew S Lawrence, Robert H Roth, Dieter Edbauer, Robin J Kleiman, Claes Wahlestedt.   

Abstract

Schizophrenia is characterized by affective, cognitive, neuromorphological, and molecular abnormalities that may have a neurodevelopmental origin. MicroRNAs (miRNAs) are small noncoding RNA sequences critical to neurodevelopment and adult neuronal processes by coordinating the activity of multiple genes within biological networks. We examined the expression of 854 miRNAs in prefrontal cortical tissue from 100 control, schizophrenic, and bipolar subjects. The cyclic AMP-responsive element binding- and NMDA-regulated microRNA miR-132 was significantly down-regulated in both the schizophrenic discovery cohort and a second, independent set of schizophrenic subjects. Analysis of miR-132 target gene expression in schizophrenia gene-expression microarrays identified 26 genes up-regulated in schizophrenia subjects. Consistent with NMDA-mediated hypofunction observed in schizophrenic subjects, administration of an NMDA antagonist to adult mice results in miR-132 down-regulation in the prefrontal cortex. Furthermore, miR-132 expression in the murine prefrontal cortex exhibits significant developmental regulation and overlaps with critical neurodevelopmental processes during adolescence. Adult prefrontal expression of miR-132 can be down-regulated by pharmacologic inhibition of NMDA receptor signaling during a brief postnatal period. Several key genes, including DNMT3A, GATA2, and DPYSL3, are regulated by miR-132 and exhibited altered expression either during normal neurodevelopment or in tissue from adult schizophrenic subjects. Our data suggest miR-132 dysregulation and subsequent abnormal expression of miR-132 target genes contribute to the neurodevelopmental and neuromorphological pathologies present in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315408      PMCID: PMC3286960          DOI: 10.1073/pnas.1113793109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  MicroRNA targeting specificity in mammals: determinants beyond seed pairing.

Authors:  Andrew Grimson; Kyle Kai-How Farh; Wendy K Johnston; Philip Garrett-Engele; Lee P Lim; David P Bartel
Journal:  Mol Cell       Date:  2007-07-06       Impact factor: 17.970

2.  Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model.

Authors:  Kimberly L Stark; Bin Xu; Anindya Bagchi; Wen-Sung Lai; Hui Liu; Ruby Hsu; Xiang Wan; Paul Pavlidis; Alea A Mills; Maria Karayiorgou; Joseph A Gogos
Journal:  Nat Genet       Date:  2008-05-11       Impact factor: 38.330

3.  Dopamine modulation of prefrontal cortical interneurons changes during adolescence.

Authors:  Kuei-Yuan Tseng; Patricio O'Donnell
Journal:  Cereb Cortex       Date:  2006-07-03       Impact factor: 5.357

4.  The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

Authors:  Robert W Buchanan; Daniel C Javitt; Stephen R Marder; Nina R Schooler; James M Gold; Robert P McMahon; Uriel Heresco-Levy; William T Carpenter
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

5.  An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP.

Authors:  Gary A Wayman; Monika Davare; Hideaki Ando; Dale Fortin; Olga Varlamova; Hai-Ying M Cheng; Daniel Marks; Karl Obrietan; Thomas R Soderling; Richard H Goodman; Soren Impey
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-24       Impact factor: 11.205

Review 6.  Neuregulin 1 in neural development, synaptic plasticity and schizophrenia.

Authors:  Lin Mei; Wen-Cheng Xiong
Journal:  Nat Rev Neurosci       Date:  2008-05-14       Impact factor: 34.870

7.  Dysregulation of miRNA 181b in the temporal cortex in schizophrenia.

Authors:  Natalie J Beveridge; Paul A Tooney; Adam P Carroll; Erin Gardiner; Nikola Bowden; Rodney J Scott; Nham Tran; Irina Dedova; Murray J Cairns
Journal:  Hum Mol Genet       Date:  2008-01-09       Impact factor: 6.150

8.  PLA(2) signaling is involved in calpain-mediated degradation of synaptic dihydropyrimidinase-like 3 protein in response to NMDA excitotoxicity.

Authors:  Renata Kowara; Kristoffer Laser Moraleja; Balu Chakravarthy
Journal:  Neurosci Lett       Date:  2007-11-05       Impact factor: 3.046

Review 9.  Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.

Authors:  T Enomoto; Y Noda; T Nabeshima
Journal:  Methods Find Exp Clin Pharmacol       Date:  2007-05

10.  microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder.

Authors:  Diana O Perkins; Clark D Jeffries; L Fredrik Jarskog; J Michael Thomson; Keith Woods; Martin A Newman; Joel S Parker; Jianping Jin; Scott M Hammond
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  126 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  Heterogeneity and individuality: microRNAs in mental disorders.

Authors:  Leif G Hommers; Katharina Domschke; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2014-11-14       Impact factor: 3.575

3.  Association study of H2AFZ with schizophrenia in a Japanese case-control sample.

Authors:  Daisuke Jitoku; Naoki Yamamoto; Yoshimi Iwayama; Tomoko Toyota; Momo Miyagi; Takeshi Enokida; Yuri Tasaka; Masakazu Umino; Asami Umino; Akihito Uezato; Yasuhide Iwata; Katsuaki Suzuki; Mitsuru Kikuchi; Tasuku Hashimoto; Nobuhisa Kanahara; Akeo Kurumaji; Takeo Yoshikawa; Toru Nishikawa
Journal:  J Neural Transm (Vienna)       Date:  2014-11-13       Impact factor: 3.575

4.  Epigenetics in the human brain.

Authors:  Isaac Houston; Cyril J Peter; Amanda Mitchell; Juerg Straubhaar; Evgeny Rogaev; Schahram Akbarian
Journal:  Neuropsychopharmacology       Date:  2012-05-30       Impact factor: 7.853

Review 5.  General principals of miRNA biogenesis and regulation in the brain.

Authors:  Dónal O'Carroll; Anne Schaefer
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

6.  The pattern of cortical dysfunction in a mouse model of a schizophrenia-related microdeletion.

Authors:  Karine Fénelon; Bin Xu; Cora S Lai; Jun Mukai; Sander Markx; Kimberly L Stark; Pei-Ken Hsu; Wen-Biao Gan; Gerald D Fischbach; Amy B MacDermott; Maria Karayiorgou; Joseph A Gogos
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

7.  Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization.

Authors:  Fani Memi; Daniela Tirziu; Irinna Papangeli
Journal:  J Vis Exp       Date:  2018-09-15       Impact factor: 1.355

8.  The environmental neurotoxicant PCB 95 promotes synaptogenesis via ryanodine receptor-dependent miR132 upregulation.

Authors:  Adam Lesiak; Mingyan Zhu; Hao Chen; Suzanne M Appleyard; Soren Impey; Pamela J Lein; Gary A Wayman
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

9.  Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy.

Authors:  Nicole R Parker; Nelson Correia; Brendan Crossley; Michael E Buckland; Viive M Howell; Helen R Wheeler
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 10.  Integrating the roles of long and small non-coding RNA in brain function and disease.

Authors:  G Barry
Journal:  Mol Psychiatry       Date:  2014-01-28       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.